Lyfebulb Initiative to Help Organ Transplant Recipients Access Innovative Solutions to Improve Daily Lives
Winner of Innovation Challenge to Receive $25,000 Grant
NEW YORK, NY, USA – February 10, 2021 – Last month, Lyfebulb, a patient-empowerment platform that connects patients with industry to support user-driven innovation, launched its first Innovation Challenge for 2021 in the area of Thriving with Transplantation. The Challenge goal is to identify new ways to help organ transplant recipients better manage their numerous daily challenges and experiences.
The global Innovation Challenge, sponsored by CSL Behring, will take place virtually in May 2021 and is open to patient entrepreneurs – those who have been affected by chronic disease as either a patient, support partner for a loved one or know someone who motivated them to start a company to develop solutions to an unmet need identified in their disease journey.
“As someone living with two organ transplants and managing the rigorous demands of being a CEO of a health-based start-up, I know first hand the many challenges that organ transplant recipients face each and every day,” explains Dr. Karin Hehenberger, CEO and Founder of Lyfebulb and transplant recipient. “At the heart of our Innovation Challenge, Lyfebulb and CSL Behring are eager to identify tangible and meaningful solutions to alleviate patient worries and improve their quality of life. Our goal is to invite fresh thinking and brilliant ideas to help organ transplant recipients not only survive but even thrive with their conditions by addressing the many obstacles, small and large, that they encounter daily.”
Submissions may span devices, diagnostics, consumer products, products for healthcare professionals, and healthcare IT to manage transplants, as well as support overall physical and mental well-being. Selected finalists will receive an invitation to pitch their company’s solutions to an expert panel of judges comprised of healthcare industry, medical and patient leaders. One winner will be awarded a $25,000 monetary grant. Competing finalists may be considered for possible partnerships or investments beyond the challenge. To apply or learn more, please visit:
The Innovation Challenge is one component of a larger partnership between Lyfebulb and CSL Behring to generate new solutions to better serve members within the transplant community. Please visit https://www.transplantlyfe.com to see the digital engagement platform, launched by Lyfebulb in partnership with CSL, for the transplant community.
Lyfebulb is a chronic disease-focused, patient empowerment platform that connects patients and industry to support user-driven innovation. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis, mental health, substance use disorder, migraine, transplantation, psoriasis, chronic cough, and chronic kidney disease. See Lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.
About CSL Behring
CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 27,000 people, and delivers its life-saving therapies to people in more than 100 countries. For inspiring stories about the promise of biotechnology, visit Vita CSLBehring.com/vita and follow us on Twitter.com/CSLBehring
For more information:
Karin Hehenberger, MD, PhD
CEO & Founder, Lyfebulb
Phone: + 1 917-575-0210